Antimicrobial Pouch for Biofilm Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic therapies are inadequate in treating and preventing biofilm-related infections, particularly in open fractures and implantable devices, as they fail to reach sufficient concentrations to effectively eradicate biofilms, leading to high infection rates and antibiotic resistance.
Innovation Solution
A therapeutic agent releasing pouch with a rate determining/controlled release membrane is developed to provide high doses of antimicrobials locally, allowing for sustained release and reloadability, effectively targeting biofilms and planktonic bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic antibiotic therapy is administered to treat biofilm infections, then the antibiotic is delivered globally to the entire system, but the concentration at the target site is insufficient to eradicate biofilms
Solution Approach 1:
The patent applies local quality by transitioning from systemic (global) antibiotic delivery to localized delivery at the infection site. The device places antibiotic-impregnated beads or patches directly into the biofilm matrix, ensuring high local concentration where needed while avoiding systemic distribution. This resolves the contradiction by achieving sufficient target site concentration through localized application rather than dilutive systemic delivery.
Solution Approach 2:
The patent uses antibiotic-impregnated beads as an intermediary carrier to deliver antibiotics directly to the biofilm. These beads are placed into the biofilm matrix and release antibiotics locally, serving as a mediator between the antibiotic source and the target biofilm tissue. This intermediary approach enables sustained high local concentrations without requiring systemic administration.
2Quantity of substance
If high doses of antibiotics are administered systemically to reach sufficient blood levels, then biofilm eradication may be achieved, but toxic side effects occur in susceptible tissues
Solution Approach 1:
The patent applies local quality by concentrating antibiotic delivery exclusively at the infection site rather than distributing it systemically. By placing antibiotic-impregnated beads directly into the biofilm, high concentrations are achieved locally without exposing susceptible tissues (liver, kidneys, cochlea) to toxic systemic levels. This resolves the contradiction between achieving effective concentration and avoiding toxicity.
Solution Approach 2:
The patent segments the antibiotic delivery system into discrete beads or patches that are placed directly at the infection site. This segmentation allows the antibiotic to be confined to the specific location needing treatment, preventing systemic circulation and associated toxic side effects while maintaining high local concentration for biofilm eradication.
3Reliability
If current antibiotic therapies are used against biofilms, then the treatment is optimized for planktonic bacteria, but biofilm bacteria remain resilient and tolerant
Solution Approach 1:
The patent applies local quality by delivering antibiotics directly into the biofilm matrix where the bacteria reside, rather than relying on systemic distribution optimized for planktonic bacteria. This localized delivery ensures the antibiotic reaches the biofilm environment with appropriate concentration and duration, overcoming the limitation of therapies optimized only for free-living bacteria.
Solution Approach 2:
The patent employs preliminary action by placing antibiotic-impregnated beads or patches directly into the biofilm before the bacteria can develop further tolerance or spread. This proactive local delivery ensures the antibiotic is already present at effective concentrations when the biofilm is most vulnerable, improving reliability compared to reactive systemic therapy optimized for planktonic forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pouch demonstrates efficacy in eradicating biofilms and planktonic bacteria, reducing infection rates by maintaining high antimicrobial concentrations at the site of infection, as shown in preliminary in vitro and in vivo tests, and offers versatility for use with various antimicrobials and implant systems.
Implementation Method 1
The body includes a rate determining membrane that controls release of the therapeutic agent to the surrounding tissue
Data Source
AI summary
Methods and devices for eradicating biofilms and planktonic bacteria are provided. In on embodiment, a therapeutic delivery device comprised of at least a port and a antimicrobial releasing pouch and one or more therapeutic agents is provided to the mammal. In one aspect of at least one embodiment the releasing pouch has an internal reservoir comprised of a membrane that is configured to contain the one or more therapeutic agents that is to be administered to the mammal and the port is in fluid communication with the pouch and configured such that the pouch can be refilled with one or more therapeutic agents via the port. In other aspect of at least one embodiment the method is able to fully eradicate 109 colony forming units (CFU) of methicillin-resistant Staphylococcus aureus (MRSA) within a 24 hr period.